Avoro Capital Drops $36.3M on Scribe Therapeutics Stock — 12.4% of the Company
SCTX is trading near its 52-week low of $17.305 (9.2% above the low).
Summary
Avoro Capital Advisors, a director and 10% owner of Scribe Therapeutics, purchased $36.3 million in stock—12.4% of the company—in the days following the IPO, a massive vote of confidence from a key life sciences investor.
Key Events · Ownership and Investor Activity · SCTX
-
Massive Post-IPO Buying Spree
Between July 24 and July 28, Avoro Capital Advisors and affiliates purchased 2,391,238 shares for $36.3 million, representing 12.4% of Scribe Therapeutics' market cap.
-
IPO Allocation and Open-Market Buys
The buying was anchored by 2,333,333 shares acquired at the $15.00 IPO price, but an additional 57,905 shares were picked up in the open market at $22.31 and $18.25—a clear willingness to pay above the offer price.
-
Ownership Concentration
Post-transaction, Avoro holds 3,088,888 shares, including converted Series B preferred stock, making it a dominant shareholder and reducing the public float.
-
Director and 10% Owner Conviction
Behzad Aghazadeh, portfolio manager of Avoro and a Scribe board member, is the controlling person behind the purchases—aligning insider knowledge with significant capital at risk.
Analysis · SCTX · Life Sciences
In the days following Scribe Therapeutics' IPO, Avoro Capital Advisors—a director and 10% owner—deployed $36.3 million to acquire shares, a sum equal to 12.4% of the company's market cap. That level of commitment from a sophisticated life sciences investor is anything but routine. Most of the buying occurred at the $15.00 IPO price, yet Avoro also scooped up shares in the open market at $22.31 and $18.25, signaling conviction even as the stock traded above the offer price. This is a cornerstone investor doubling down immediately after the IPO, a move that dramatically shrinks the public float and telegraphs deep confidence in the company's pipeline.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 553 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCTX was trading at $18.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $292.2M. The 52-week trading range was $17.31 to $22.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.